NOT FOR DISTRIBUTION
Header cover image

Market Cap

UK£271.1m

Last Updated

2021/05/05 18:02 UTC

Data Sources

Company Financials +

Executive Summary

Tristel plc develops, manufactures, and supplies infection and contamination control, and hygiene products in the United Kingdom and internationally. More Details


Snowflake Analysis

Flawless balance sheet with reasonable growth potential.

Share Price & News

How has Tristel's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: TSTL is not significantly more volatile than the rest of UK stocks over the past 3 months, typically moving +/- 7% a week.

Volatility Over Time: TSTL's weekly volatility (7%) has been stable over the past year.


Market Performance


7 Day Return

0%

TSTL

4.4%

GB Medical Equipment

0.8%

GB Market


1 Year Return

12.3%

TSTL

1.9%

GB Medical Equipment

26.4%

GB Market

Return vs Industry: TSTL exceeded the UK Medical Equipment industry which returned 1.5% over the past year.

Return vs Market: TSTL underperformed the UK Market which returned 25% over the past year.


Shareholder returns

TSTLIndustryMarket
7 Day0%4.4%0.8%
30 Day-10.2%12.7%4.5%
90 Day-7.3%1.7%8.2%
1 Year13.6%12.3%3.8%1.9%31.9%26.4%
3 Year96.2%87.0%21.9%15.0%12.2%-0.8%
5 Year418.0%365.6%45.0%33.1%49.1%21.0%

Long-Term Price Volatility Vs. Market

How volatile is Tristel's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Tristel undervalued compared to its fair value and its price relative to the market?

31.7%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: TSTL (£5.75) is trading below our estimate of fair value (£8.42)

Significantly Below Fair Value: TSTL is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: TSTL's PE Ratio (49.5x) is in line with the GB Medical Equipment industry average.

PE vs Market: TSTL is poor value based on its PE Ratio (49.5x) compared to the UK market (25.5x).


Price to Earnings Growth Ratio

PEG Ratio: TSTL is poor value based on its PEG Ratio (2.2x)


Price to Book Ratio

PB vs Industry: TSTL is overvalued based on its PB Ratio (9.1x) compared to the GB Medical Equipment industry average (3.6x).


Future Growth

How is Tristel forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

23.0%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: TSTL's forecast earnings growth (23% per year) is above the savings rate (0.9%).

Earnings vs Market: TSTL's earnings (23% per year) are forecast to grow faster than the UK market (17.9% per year).

High Growth Earnings: earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: TSTL's revenue (19.6% per year) is forecast to grow faster than the UK market (5.4% per year).

High Growth Revenue: TSTL's revenue (19.6% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: TSTL's Return on Equity is forecast to be low in 3 years time (17%).


Past Performance

How has Tristel performed over the past 5 years?

17.4%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: TSTL has high quality earnings.

Growing Profit Margin: TSTL's current net profit margins (15.7%) are lower than last year (16.2%).


Past Earnings Growth Analysis

Earnings Trend: TSTL's earnings have grown by 17.4% per year over the past 5 years.

Accelerating Growth: TSTL's earnings growth over the past year (13.8%) is below its 5-year average (17.4% per year).

Earnings vs Industry: TSTL earnings growth over the past year (13.8%) underperformed the Medical Equipment industry 13.8%.


Return on Equity

High ROE: TSTL's Return on Equity (18.2%) is considered low.


Financial Health

How is Tristel's financial position?


Financial Position Analysis

Short Term Liabilities: TSTL's short term assets (£17.2M) exceed its short term liabilities (£5.3M).

Long Term Liabilities: TSTL's short term assets (£17.2M) exceed its long term liabilities (£5.8M).


Debt to Equity History and Analysis

Debt Level: TSTL is debt free.

Reducing Debt: TSTL had no debt 5 years ago.

Debt Coverage: TSTL has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: TSTL has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet


Dividend

What is Tristel current dividend yield, its reliability and sustainability?

1.07%

Current Dividend Yield


Dividend Yield vs Market

Notable Dividend: TSTL's dividend (1.07%) isn’t notable compared to the bottom 25% of dividend payers in the UK market (1.36%).

High Dividend: TSTL's dividend (1.07%) is low compared to the top 25% of dividend payers in the UK market (4.09%).


Stability and Growth of Payments

Stable Dividend: TSTL's dividend payments have been volatile in the past 10 years.

Growing Dividend: TSTL's dividend payments have increased over the past 10 years.


Current Payout to Shareholders

Dividend Coverage: With its reasonable payout ratio (55.6%), TSTL's dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: TSTL's dividends in 3 years are forecast to be covered by earnings (60.9% payout ratio).


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.9yrs

Average board tenure


CEO

Paul Swinney (61 yo)

28.33yrs

Tenure

UK£415,000

Compensation

Mr. Paul C. Swinney serves as the Chief Executive Officer of Tristel Plc. since 1993 and serves as its Director. Mr. Swinney started his career with Brown, Shipley & Co in 1980. He worked for the European ...


CEO Compensation Analysis

Compensation vs Market: Paul's total compensation ($USD577.26K) is about average for companies of similar size in the UK market ($USD724.82K).

Compensation vs Earnings: Paul's compensation has been consistent with company performance over the past year.


Board Members

Experienced Board: TSTL's board of directors are not considered experienced ( 1.9 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: TSTL insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 4%.


Top Shareholders

Company Information

Tristel plc's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Tristel plc
  • Ticker: TSTL
  • Exchange: AIM
  • Founded: 1993
  • Industry: Health Care Supplies
  • Sector: Healthcare
  • Market Cap: UK£271.080m
  • Shares outstanding: 47.06m
  • Website: https://www.tristel.com

Number of Employees


Location

  • Tristel plc
  • Lynx Business Park
  • Unit 1B
  • Snailwell
  • Cambridgeshire
  • CB8 7NY
  • United Kingdom

Listings


Biography

Tristel plc develops, manufactures, and supplies infection and contamination control, and hygiene products in the United Kingdom and internationally. The company operates through three segments: Hospital M...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/05/05 18:02
End of Day Share Price2021/05/05 00:00
Earnings2020/12/31
Annual Earnings2020/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.